Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | YES1 | P07947 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.48 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518881 | 0.85 | PIK3CB (0.46) | JAK2KDRPIK3CBPRKDCMAPT | |
| SCHEMBL13632607 | 0.84 | MAPKAPK2 (0.52) | JAK2KDRMAPKAPK2ABL1NTRK1 | |
| SCHEMBL18527544 | 0.79 | JAK2 (0.61) | JAK2KDRPLK4MAPKAPK2ABL1 | |
| SCHEMBL12801112 | 0.77 | JAK2 (1.00) | JAK2PLK4 | |
| SCHEMBL2572202 | 0.77 | JAK2 (0.58) | JAK2PLK4ITKPIK3CBPRKDC | |
| SCHEMBL13859374 | 0.77 | JAK2 (0.69) | JAK2PLK4ITKMAPTMAPK1 | |
| SCHEMBL16514799 | 0.76 | JAK2 (0.66) | JAK2PLK4ITKSYK | |
| SCHEMBL16513771 | 0.76 | JAK2 (0.65) | JAK2PLK4MAPKAPK2ITKMAPT | |
| SCHEMBL29576008 | 0.76 | JAK2 (0.65) | JAK2PLK4MAPKAPK2ITKMAPT | |
| SCHEMBL21155959 | 0.75 | JAK2 (0.63) | JAK2PLK4MAPKAPK2ITKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | HRH4, NR1H2, NR1H3 | JAK2 1723/4885KDR 1599/4885PLK4 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.